Recent

% | $
Quotes you view appear here for quick access.

Celldex Therapeutics, Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • sonquiqua sonquiqua May 22, 2012 8:09 PM Flag

    Submission category revisited

    it seems that the error may have been that CLDX believed they could submit a phase 2 as late breaking when only phase 3 trials qualify as such... as I posted a few minutes earlier (new topic):

    Late-Breaking Abstracts

    The ASCO Late-Breaking Abstracts Policy allows for the submission of Late-Breaking Abstracts only for randomized phase III trials for which no preliminary data are available at the time of the abstract submission deadline (February 1, 2012), but for which a preplanned analysis of the primary endpoint is scheduled after that date but before April 2, 2012 (deadline for the final, updated Late-Breaking Abstract). During abstract submission, you will be required to provide the date of planned analysis. The policy is not a mechanism to allow for updated data to be submitted later when preliminary data are available by the abstract submission deadline.

    and here is the detail "how to submit" (pretty clear, I'm afraid)
    http://chicago2012.asco.org/Abstracts/LateBreakingAbstracts/SubmissionGuidelines.aspx

 
CLDX
27.57+0.43(+1.58%)10:07 AMEDT